Become a Patron!
True Information is the most valuable resource and we ask you to give back.

As the medication’s designers guaranteed in a new meeting, we currently have a companion looked into logical article that puts forth the defense for EpiVacCorona, Russia’s most recent Covid immunization. Despite the fact that the examination didn’t show up until March 25, the actual medication won administrative endorsement back in October 2020 and has been accessible to Russian patients outside clinical preliminaries for quite a long time. Until yesterday, the solitary public data about the antibody was restricted to two licenses, a few assertions by Russia’s purchaser assurance organization (which controls the foundation that created EpiVacCorona), and a couple of meetings with the medication’s makers. Sadly, the hotly anticipated proof fails to impress anyone. Outstandingly, researchers delivered the article in a mostly secret Russian diary called Infection and Immunity, notwithstanding signs from wellbeing authorities that the exploration would show up in a more definitive outlet like The New English Journal of Medicine or The Lancet (which distributed the principal peer-inspected proof for the “Sputnik V” immunization). Meduza explored the EpiVacCorona article and requested that three specialists survey its qualities and shortcomings.